A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | CATEGORY | SUBCATEGORY | TREATMENT | EFFECT | SIDES | EFFICACY | SAFETY | MONTHLY PRICE | |||||||||||||||||||
2 | antiandrogen | SARM | andarine S4 | ? | ? | ? | ? | ? | |||||||||||||||||||
3 | ? | ? | bisindolylmaleimide | PKC inhibitor | ? | ? | ? | ? | |||||||||||||||||||
4 | ? | ? | erlotinib | EGFR inhibitor | ? | ? | ? | ? | |||||||||||||||||||
5 | ? | ? | fevipiprant | ? | ? | ? | ? | high | |||||||||||||||||||
6 | not working | other | procyanidin B-2 | none | ? | ? | ? | ? | |||||||||||||||||||
7 | ? | ? | rapamycin/sirolimus | mTOR inhibition | ? | ? | ? | ? | |||||||||||||||||||
8 | ? | ? | adenosine | ? | ? | ? | ? | ? | |||||||||||||||||||
9 | ? | ? | setipiprant | ? | ? | ? | ? | high | |||||||||||||||||||
10 | alternative treatments | other | botox injection | ? | ? | ? | ? | ? | |||||||||||||||||||
11 | alternative treatments | other | dermarolling | ? | scalp infections | ? | ? | low | |||||||||||||||||||
12 | not working | other | lllt | none | none | ? | ? | medium | |||||||||||||||||||
13 | not working | other | prp | none | none | ? | ? | high | |||||||||||||||||||
14 | alternative treatments | other | scalp massages | decrease calcification | none | ? | ? | low | |||||||||||||||||||
15 | not working | other | trinov | none | none | ? | ? | high | |||||||||||||||||||
16 | antiandrogen | 5α-R | dutasteride | -95% DHT whole body | sexual dysfunction, depression, and breast enlargement | 5α-R 1° | 5α-R 4° | low | |||||||||||||||||||
17 | antiandrogen | 5α-R | finasteride/proscar/propecia | -70% DHT whole body | sexual dysfunction, depression, and breast enlargement | 5α-R 2° | 5α-R 3° | low | |||||||||||||||||||
18 | antiandrogen | 5α-R | saw palmetto/serenoa repens | about half as effective as finasteride | sexual dysfunction, depression, and breast enlargement | 5α-R 3° | 5α-R 2° | low | |||||||||||||||||||
19 | antiandrogen | 5α-R/estrogen | alfatradiol/pantostin/17α-estradiol | never been proven to inhibit 5-ar in vivo, it's supposed to be a weak 5-ARI | none | 5α-R 4° | 5α-R 1° | low | |||||||||||||||||||
20 | antiandrogen | CYP17A1 | ketoconazole/nizoral | It was speculated that antifungal properties of ketoconazole reduce scalp microflora and consequently may reduce follicular inflammation that contributes to alopecia. | none | ? | ? | low | |||||||||||||||||||
21 | antiandrogen | MCRA | eplerenone/aldactone | blocks aldosterone, downregulates TGF-b and p53, and reverses fibrosis | Risk of gyno with eplerenone is only .5% compared with 10% for spironolactone. | ? | ? | ? | |||||||||||||||||||
22 | antiandrogen | MCRA | spironolactone | blocks aldosterone, downregulates TGF-b and p53, and reverses fibrosis | The most common side effect of spironolactone is frequent urination. Other general side effects include dehydration, hyponatremia (low sodium levels), mild hypotension (low blood pressure), ataxia (muscle incoordination), drowsiness, dizziness, dry skin, and rashes. Because of its antiandrogenic activity, spironolactone can, in men, cause breast tenderness, gynecomastia (breast development), feminization in general, and demasculinization, as well as sexual dysfunction including loss of libido and erectile dysfunction, although these side effects are usually confined to high doses of spironolactone. | ? | ? | ? | |||||||||||||||||||
23 | antiandrogen | NSAA | apalutamide | ? | ? | ? | ? | ? | |||||||||||||||||||
24 | antiandrogen | NSAA | bicatulamide | ? | Gynecomastia > 40%, The core side effects of NSAAs such as gynecomastia, sexual dysfunction, and hot flashes occur at similar rates with the different drugs. | ? | ? | ? | |||||||||||||||||||
25 | antiandrogen | NSAA | darolutamide | ? | ? | ? | ? | ? | |||||||||||||||||||
26 | antiandrogen | NSAA | enzalutamide | ? | ? | ? | ? | ? | |||||||||||||||||||
27 | antiandrogen | NSAA | flutamide | bicatulamide is more potent and safer for the treatment of prostate cancer | The core side effects of NSAAs such as gynecomastia, sexual dysfunction, and hot flashes occur at similar rates with the different drugs. | bicatulamide is a better alternative | ? | ? | |||||||||||||||||||
28 | antiandrogen | NSAA | hydroxyflutamide/oh-flutamide | same as flutamide? | ? | ? | ? | ? | |||||||||||||||||||
29 | antiandrogen | NSAA | nilutamide | bicatulamide is more potent and safer for the treatment of prostate cancer | The core side effects of NSAAs such as gynecomastia, sexual dysfunction, and hot flashes occur at similar rates with the different drugs. | bicatulamide is a better alternative | ? | ? | |||||||||||||||||||
30 | antiandrogen | NSAA | ru58841 | defends against dht topically | ? | ? | ? | low | |||||||||||||||||||
31 | antiandrogen | NSAA | topilutamide/fluridil/eucapil | poor reviews, marketed as a topical medication for the treatment of pattern hair loss | none | ? | ? | ? | |||||||||||||||||||
32 | antiandrogen | other | zyx | ? | ? | ? | ? | ? | |||||||||||||||||||
33 | antiandrogen | SAA | clascoterone/cb-03-01/breezula | the topical potency of the medication was greater than that of progesterone, flutamide, and finasteride and was equivalent to that of cyproterone acetate. Likewise, it is significantly more efficacious as an antiandrogen than other AR antagonists such as enzalutamide and spironolactone in scalp dermal papilla cells and sebocytes in vitro. | none | ? | ? | high | |||||||||||||||||||
34 | antiandrogen | SAA | cyproterone acetate/CPA/androcur | halt further progression of scalp hair loss in men, increased head hair | gynecomastia (breast development) and feminization, low sex hormone levels, reversible infertility, sexual dysfunction, fatigue, depression, weight gain, and elevated liver enzymes | bicatulamide is a better alternative | ? | ? | |||||||||||||||||||
35 | growth stimulants | estrogen | estriol | weak estrogen, may have preferential affinity for ERβ. | ? | ? | ? | ? | |||||||||||||||||||
36 | growth stimulants | estrogen | s-equol | (S)-Equol preferentially binds estrogen receptor beta. | ? | ? | ? | ? | |||||||||||||||||||
37 | growth stimulants | other | bimatoprost | ? | ? | ? | ? | ? | |||||||||||||||||||
38 | growth stimulants | other | cyclosporine | calcineurin inhibitor, used as an immunosuppressant medication | dangerous because immunosuppressant | ? | ? | ? | |||||||||||||||||||
39 | growth stimulants | other | essential oil | ? | ? | ? | ? | low | |||||||||||||||||||
40 | growth stimulants | other | isotretinoin/accutane | ? | ? | ? | ? | ? | |||||||||||||||||||
41 | growth stimulants | other | latanoprost | ? | ? | ? | ? | ? | |||||||||||||||||||
42 | growth stimulants | other | minoxidil | open the potassium channels | ? | ? | ? | low | |||||||||||||||||||
43 | growth stimulants | other | sandalore | Increases IGF-1 and keratinocytes. Reduces TGFbeta2: required for hair follicle neogenesis | ? | ? | ? | low | |||||||||||||||||||
44 | growth stimulants | other | stemoxidyne | creates a hypoxia environment | none | ? | ? | low | |||||||||||||||||||
45 | growth stimulants | other | tretinoin | increase minoxidil absorption | ? | ? | ? | ? | |||||||||||||||||||
46 | growth stimulants | PG | cetirizine | reduce PGD2, studies showing topical cetirizine 1% works for stimulating regrowth | ? | ? | ? | ? | |||||||||||||||||||
47 | growth stimulants | PG | desloratine | reduce PGD2, basically the same than cetirizine but more stable in alcohol. So it makes a good choice for those already mixing their own topicals. | ? | ? | ? | ? | |||||||||||||||||||
48 | growth stimulants | PG | dinoprost/prostaglandin F2alpha | ? | ? | ? | ? | ? | |||||||||||||||||||
49 | growth stimulants | PG | oc000459 | PG2 inhibitor | ? | ? | ? | ? | |||||||||||||||||||
50 | growth stimulants | PG | ramatroban | PG2 inhibitor | ? | ? | ? | ? | |||||||||||||||||||
51 | growth stimulants | PG | sw033291 | potent inhibitor of 15-PGDH which metabolizes PGE1, PGE2 and PGF2a | ? | ? | ? | ? | |||||||||||||||||||
52 | growth stimulants | PG | tm30089 | PG2 inhibitor | ? | ? | ? | ? | |||||||||||||||||||
53 | growth stimulants | PG/WNT | pge2 | increase PGE2, GSK3B inhibitor | ? | ? | ? | ? | |||||||||||||||||||
54 | growth stimulants | SHH | halcinonide | https://www.hairlosstalk.com/interact/threads/curis-p-g-and-the-lost-baldness-cure.127846/page-7#post-1888838 | ? | ? | ? | ? | |||||||||||||||||||
55 | growth stimulants | SHH | purmorphamine | sonic hedgehog agonist | cancer risk | ? | ? | ? | |||||||||||||||||||
56 | growth stimulants | SHH | sag/smoothened agonist | sonic hedgehog agonist | cancer risk | ? | ? | ? | |||||||||||||||||||
57 | growth stimulants | WNT | chir99021 | GSK3B inhibitor | ? | ? | ? | ? | |||||||||||||||||||
58 | growth stimulants | WNT | curcumin | DKK1 inhibitor | ? | ? | ? | ? | |||||||||||||||||||
59 | growth stimulants | WNT | estrogen | DKK1 + GSK3B inhibitor | ? | ? | ? | ? | |||||||||||||||||||
60 | growth stimulants | WNT | gallocyanine | DKK1 inhibitor | ? | ? | ? | ? | |||||||||||||||||||
61 | growth stimulants | WNT | lithium chloride | GSK3B inhibitor | ? | ? | ? | ? | |||||||||||||||||||
62 | growth stimulants | WNT | samumed sm04554 | GSK3B inhibitor | ? | ? | ? | ? | |||||||||||||||||||
63 | growth stimulants | WNT | vpa/valproic acid | GSK3B inhibitor | ? | ? | ? | ? | |||||||||||||||||||
64 | growth stimulants | WNT | way-262611 | DKK1 inhibitor | ? | ? | ? | ? | |||||||||||||||||||
65 | growth stimulants | WNT | way-316606 | SFRP1 inhibitor | ? | ? | ? | ? | |||||||||||||||||||
66 | growth stimulants | peptide | epitalon | synthetic peptide, telomerase activator, and putative anti-aging drug | ? | ? | ? | ? | |||||||||||||||||||
67 | growth stimulants | peptide | tb-500/thymosin-beta4 | The main purpose of this peptide is to promote healing. It also promotes creation of new blood and muscle cells. The healing effects of TB-500 have been observed in tendons, ligaments, muscle, skin, heart, and the eyes. Thymosin beta-4 is naturally produced in higher concentration where tissue has been damaged. | ? | ? | ? | ? | |||||||||||||||||||
68 | growth stimulants | peptide | PTD-DBM | Applying PTD-DBM for 28 days to the hairless area, the hair follicles will be healthy and the hair will come back. If you apply VPA (valproic acid), a chemical that activates the winter signaling system, the hair growth effect is higher. | ? | ? | ? | ? |